Retatrutide vs Orforglipron

Retatrutide and Orforglipron are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Retatrutide, a pioneering investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon, is under development by Eli Lilly. In a Phase 2 trial conducted by Jastreboff et al. (2023) published in NEJM, a 12 mg dose resulted in an impressive mean body weight reduction of 24.2% over 48 weeks, with all participants achieving at least 5% weight loss. This outcome suggests a robust potential for Retatrutide in obesity management. Currently, multiple Phase 3 TRIUMPH trials are underway, with TRIUMPH-4 expected to report findings in December 2025, including data on average weight loss of up to 71.2 lbs and improvement in osteoarthritis-related pain. Anticipated FDA approval is projected for 2027-2028, which could position Retatrutide as a significant player in the weight management landscape. The peptide also demonstrates improvements in glycemic control among individuals with type 2 diabetes, further broadening its therapeutic implications.

Orforglipron (LY3502970) stands out as a small-molecule, non-peptide oral GLP-1 receptor agonist, also developed by Eli Lilly. Notably, it is included in this comparison due to its functional similarity with peptide-based GLP-1 agonists. Currently in the Phase III ATTAIN trial program, Orforglipron has demonstrated promising results in Phase II trials, showing weight loss outcomes comparable to those of injectable GLP-1 agonists. If approved, it would mark the first oral non-peptide GLP-1 agonist available, potentially offering a more convenient dosing regimen. The ability to administer Orforglipron once daily without food restrictions may enhance patient adherence compared to existing therapies like oral semaglutide. This unique formulation could address some of the barriers associated with injectable therapies, making it a noteworthy contender in the management of type 2 diabetes and obesity.

Both Retatrutide and Orforglipron are currently being investigated for their roles in weight management and metabolic health. The focus on these areas reflects a growing interest in developing effective treatments for obesity and its associated metabolic disorders. While Retatrutide is specifically noted for its triple agonistic action, Orforglipron’s oral administration format offers a different approach within the same therapeutic context. Despite their shared applications, each compound presents unique mechanisms and potential advantages that warrant further exploration in clinical settings.

Safety profiles for Retatrutide and Orforglipron reveal common gastrointestinal (GI) side effects, which are characteristic of GLP-1 receptor agonists. For Retatrutide, dose-related GI adverse events were observed in 13-63% of participants, including nausea, vomiting, diarrhea, and constipation, primarily classified as mild to moderate. Notably, a lower initial dose (2 mg vs 4 mg) may mitigate some of these effects. Additionally, dose-dependent increases in heart rate were noted, peaking at 24 weeks before declining. In contrast, Orforglipron reported similar GI side effects, with nausea occurring in 30-40% and vomiting in 14-22% of participants. Discontinuation rates due to GI adverse events were approximately 10-17%, which is lower than those observed with other GLP-1 agonists such as danuglipron. Heart rate increases of 2-4 bpm were also consistent with the GLP-1 class. These safety considerations are critical for researchers assessing the viability of these compounds in clinical applications.